BioCardia, Inc. Common Stock vs. Kymera Therapeutics, Inc. Common Stock
BCDA
BioCardia, Inc. Common Stock
$0.96 -2.87%
VS KYMRKymera Therapeutics, Inc. Common Stock
$122.62 -3.68%
BioCardia, Inc. Common Stock and Kymera Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| BCDA | KYMR | |
|---|---|---|
| Market Cap | $15.00 million | $10.59 billion |
| Revenue (TTM) | — | $105.00 million |
| Net Income (TTM) | — | $-299,601,000 |
KYMR leads on 1 of 1 size & scale factors.
Valuation
| BCDA | KYMR | |
|---|---|---|
| Price / Book | — | 7.01 |
| Price / Sales | — | 100.82 |
BCDA and KYMR split the valuation factors evenly.
Profitability
| BCDA | KYMR | |
|---|---|---|
| Net Margin | — | -285.34% |
| Return on Equity | — | -19.85% |
BCDA and KYMR split the profitability factors evenly.
Risk & Sentiment
| BCDA | KYMR | |
|---|---|---|
| Short Interest | 0.00% | 0.24% |
BCDA leads on 1 of 1 risk & sentiment factors.
Dig deeper: BCDA overview, BCDA financials, KYMR overview, KYMR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.